AIM ImmunoTech CEO Thomas Equels Buys 24,000 Shares

What Happened
Thomas K. Equels, CEO, President and a director of AIM ImmunoTech Inc. (AIM), made an open-market purchase of 24,000 shares on 2026-09-17 at $0.21 per share, for a total cash outlay of $4,992. This was a straight purchase (transaction code P), which is a direct buy of company stock rather than a sale or an option exercise.

Key Details

• Transaction date: 2026-09-17 (reported on Form 4 filed 2026-09-18, accession 0001493152-26-043246)
• Price: $0.21 per share; Shares bought: 24,000; Total value: $4,992
• Transaction type/code: Open-market purchase (P)
• Shares owned after the transaction: not specified in the provided summary — check the full Form 4 for post-transaction holdings
• Footnotes/plan: no 10b5-1 plan, tax withholding, or other special notes provided in the supplied data
• Timeliness: Filing appears timely (transaction 9/17, Form 4 filed 9/18)

Context
This is a small, out-of-pocket purchase (under $5k). Purchases by executives can signal personal confidence, but the low dollar amount here limits how informative it is on its own. For a complete view, retail investors should review the full Form 4 to see total holdings and any related disclosures, and consider this trade alongside broader insider activity and company fundamentals.